15 Amendments of Christofer FJELLNER related to 2016/2057(INI)
Amendment 166 #
Motion for a resolution
Paragraph 2
Paragraph 2
Amendment 199 #
Motion for a resolution
Paragraph 4
Paragraph 4
Amendment 223 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Recalls that IP rights allows a legal monopolimited period of exclusivity, which needs to be carefully regulated to avoid conflict with the right to health protection and to promote quality of innovation and competitiveness;
Amendment 232 #
Motion for a resolution
Paragraph 6
Paragraph 6
Amendment 242 #
Motion for a resolution
Paragraph 7
Paragraph 7
Amendment 259 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. DeplorNotes the large number of litigation cases aiming to delayon generic entrys;
Amendment 305 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Believes that a fair price should cover the cost of the drug development and production, plus a margin of profitprices of medicines should reflect the value they bring to patients, healthcare systems as well as society, further the prices should provide an incentive to invest in new therapies;
Amendment 375 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Calls for EU-wide measures to guarantee the right of patients to universal, affordable, effective, safe and timely access to essential and innovative therapies, and to guarantee the sustainability of EU public health care systems;
Amendment 382 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Calls for EU-wide measures on the pharmaceutical market to reinforce thto facilitate negotiation capacities of Member States in order to achieve fair priensure patient access forto medicines;
Amendment 412 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Calls on the Commission to analyse the overall impact of IP inhow to best promotinge innovation, especially the impact of supplementary protection certificates (SPCs), data exclusivity or market exclusivity on competitiveness and quality of innovation, and to set strict limits on these practices;
Amendment 429 #
Motion for a resolution
Paragraph 21
Paragraph 21
21. Calls on the Commission to promote open data in private research, especially where public funding is involved, and to establish conditions such as affordable pricing and non-exclusivity, or co-ownership of IP for projects funded by EU public grants such as Horizon 2020where public funding is involved;
Amendment 471 #
Motion for a resolution
Paragraph 24
Paragraph 24
24. Calls on the Commission to set up a framework to promote, guarantee and reinforce the competitiveness of generic medicines, guaranteeing their faster entry onto the market andimprove the competitiveness of generic medicines by monitoring unfair practices in accordance with Articles 101 and 102 of the TFEU, and to present a biannual report in this regard;
Amendment 496 #
Motion for a resolution
Paragraph 25
Paragraph 25
25. Calls on the Commission to propose legislation on a European system for health technology assessment as soon as possible, and to assess added-value medicines compared with the best available alternative; also calls on the Commission to harmonise pricing and reimbursement criteria to take into account the level of innovation and the social and economic cost-benefit analysis, and to put in place a European classification on the added value level of medicines;
Amendment 546 #
Motion for a resolution
Paragraph 29
Paragraph 29
29. Calls on the Commission and the Council to explore new measures to control pricesublic expenditure on health care, such as horizontal scanning and coordinating joint procurements;
Amendment 586 #
Motion for a resolution
Paragraph 35
Paragraph 35